Your browser doesn't support javascript.
loading
Neisseria meningitidis serogroup C polysaccharide and serogroup B outer membrane vesicle conjugate as a bivalent meningococcus vaccine candidate
Fukasawa, Lucila O; Gorla, Maria Maria Cecília O; Schenkman, Rocilda P F; Garcia, Ligiane R; Carneiro, Sylvia M; Raw, Isaias; Tanizaki, Martha M.
Affiliation
  • Fukasawa, Lucila O; Instituto Butantan. São Paulo. BR
  • Gorla, Maria Maria Cecília O; s.af
  • Schenkman, Rocilda P F; Instituto Butantan. São Paulo. BR
  • Garcia, Ligiane R; Instituto Butantan. São Paulo. BR
  • Carneiro, Sylvia M; Instituto Butantan. São Paulo. BR
  • Raw, Isaias; Instituto Butantan. São Paulo. BR
  • Tanizaki, Martha M; Instituto Butantan. São Paulo. BR
Vaccine ; 17(23-24): 2951-2958, 1999.
Article in English | Sec. Est. Saúde SP, SESSP-IBPROD, Sec. Est. Saúde SP, SESSP-IBACERVO | ID: biblio-1068324
Responsible library: BR78.1
Localization: BR78.1
ABSTRACT
Neisseria meningitidis serogroup C polysaccharide (PS C) was conjugated to serogroup B outer membrane vesicles (OMV) in order to test the possibility of obtaining a bivalent group B and C meningococcus vaccine. The conjugate and controls were injected intraperitoneally into groups of ten mice with boosters on days 14 and 28 after the primary immunization. The following groups were used as control (i) PS C; (ii) PS C plus OMV; (iii) OMV; and (iv) saline. The serum collected on days 0, 14, 28 and 42 were tested by enzyme-linked immunosorbent assay (ELISA) for PS C and OMV, and by complement mediated bactericidal assay against serogroups B and C. ELISA for PS C as well as bactericidal titres against serogroup C meningococci of the conjugated vaccine increased eight-fold (ELISA) and 32 fold (bactericidal) after 42 days in comparison with the PS C control group. ELISA for OMV and bactericidal titre against serogroup B meningococci of the conjugate showed no significant difference in comparison with the OMV containing controls. Furthermore, Western Blot assay of the conjugate immune serum did not bind OMV class four protein which is related to the complement dependent antibody suppressor. The results indicate that the PS C-OMV conjugate could be a candidate for a bivalent vaccine toward serogroups B and C meningococci.
Subject(s)
Search on Google
Collection: National databases / Brazil Health context: SDG3 - Health and Well-Being / SDG3 - Target 3.3 End transmission of communicable diseases Health problem: Target 3.3: End transmission of communicable diseases / Meningitis Database: Sec. Est. Saúde SP / SESSP-IBACERVO / SESSP-IBPROD Main subject: Meningococcal Vaccines / Meningitis, Meningococcal / Neisseria meningitidis Limits: Female / Humans / Male Language: English Journal: Vaccine Year: 1999 Document type: Article Institution/Affiliation country: Instituto Butantan/BR
Search on Google
Collection: National databases / Brazil Health context: SDG3 - Health and Well-Being / SDG3 - Target 3.3 End transmission of communicable diseases Health problem: Target 3.3: End transmission of communicable diseases / Meningitis Database: Sec. Est. Saúde SP / SESSP-IBACERVO / SESSP-IBPROD Main subject: Meningococcal Vaccines / Meningitis, Meningococcal / Neisseria meningitidis Limits: Female / Humans / Male Language: English Journal: Vaccine Year: 1999 Document type: Article Institution/Affiliation country: Instituto Butantan/BR
...